nach oben

Erschienen in:

01.12.2012 | Original article

Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer

verfasst von: A. Singer, Y. Deuse, U. Koch, T. Hölscher, D. Pfitzmann, C. Jakob, S. Hehlgans, G.B. Baretton, A. Rentsch, M. Baumann, M.H. Muders, M. Krause

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Studies have shown that GIPC1/Synectin is an essential adaptor protein of receptors that play an important role in cancer progression and therapy resistance. This is the first study to explore the role of GIPC1/Synectin in radioresistance of prostate cancer and as a possible predictive marker for outcome of primary radiation therapy.

Materials and methods

The effect of RNA interference-mediated GIPC1/Synectin depletion on clonogenic cell survival after irradiation with 0, 2, 4, or 6 Gy was assayed in two different GIPC1/Synectin-expressing human prostate cancer cell lines. The clinical outcome data of 358 men who underwent radiotherapy of prostate cancer with a curative intention were analyzed retrospectively. Uni- and multivariate analysis was performed of prostate-specific antigen recurrence-free survival and overall survival in correlation with protein expression in pretreatment biopsy specimens. Protein expression was evaluated by standard immunohistochemistry methods.

Results

In cell culture experiments, no change was detected in radiosensitivity after depletion of GIPC1/Synectin in GIPC1/Synectin-expressing prostate cancer cell lines. Furthermore, there was no correlation between GIPC1/Synectin expression in human pretreatment biopsy samples and overall or biochemical recurrence-free survival after radiotherapy in a retrospective analysis of the study cohort.

Conclusion

Our results do not show a predictive or prognostic function of GIPC1/Synectin expression for the outcome of radiotherapy in prostate cancer. Furthermore, our in vitro results do not support a role of GIPC1 in the cellular radiation response. However, the role of GIPC1 in the progression of prostate cancer and its precursors should be subject to further research.

(n.d.) (1997) Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035–1041

Akakura K, Suzuki H, Ichikawa T et al (2006) A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 36:789–793PubMedCrossRef

Awan A, Lucic MR, Shaw DM et al (2002) 5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasis. Biochem Biophys Res Commun 290:1030–1036PubMedCrossRef

Casa AJ, Dearth RK, Litzenburger BC et al (2008) The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 13:3273–3287PubMedCrossRef

Chittenden TW, Pak J, Rubio R et al (2010) Therapeutic implications of GIPC1 silencing in cancer. PLoS One 5:e15581PubMedCrossRef

Chittenden TW, Claes F, Lanahan AA et al (2006) Selective regulation of arterial branching morphogenesis by synectin. Dev Cell 10:783–795PubMedCrossRef

Choi JS, Paek AR, Kim SY, You HJ (2010) GIPC mediates the generation of reactive oxygen species and the regulation of cancer cell proliferation by insulin-like growth factor-1/IGF-1R signaling. Cancer Lett 294:254–263PubMedCrossRef

De Vries L, Elenko E, McCaffery JM et al (1998) RGS-GAIP, a GTPase-activating protein for Galphai heterotrimeric G proteins, is located on clathrin-coated vesicles. Mol Biol Cell 9:1123–1134

Dolezel M, Odrazka K, Vaculikova M et al (2010) Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol 186:197–202PubMedCrossRef

10.

El Mourabit H, Poinat P, Koster J et al (2002) The PDZ domain of TIP-2/GIPC interacts with the C-terminus of the integrin alpha5 and alpha6 subunits. Matrix Biol 21:207–214CrossRef

11.

Ellis LM (2006) The role of neuropilins in cancer. Mol Cancer Ther 5:1099–1107PubMedCrossRef

12.

Fleming IDea (1997) AJCC Cancer Staging Manual. In: American Joint Committee on Cancer (eds.) 5th edn. Philadelphia, Lippincott-Ravens Publishers, pp 220–221

13.

Gao Y, Li M, Chen W, Simons M (2000) Synectin, syndecan-4 cytoplasmic domain binding PDZ protein, inhibits cell migration. J Cell Physiol 184:373–379PubMedCrossRef

14.

Ghadjar P, Gwerder N, Manser P et al (2010) High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer. Strahlenther Onkol 186:687–692PubMedCrossRef

15.

Hermans K, Claes F, Vandevelde W et al (2010) Role of synectin in lymphatic development in zebrafish and frogs. Blood 116:3356–3366PubMedCrossRef

16.

Hoosein NM, Boyd DD, Hollas WJ et al (1991) Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun 3:255–264PubMed

17.

Horoszewicz JS, Leong SS, Kawinski E et al (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43:1809–1818PubMed

18.

Hoskin PJ, Rojas AM, Bownes PJ et al (2012) Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 103:217–222PubMedCrossRef

19.

Hsu SM, Raine L, Fanger H (1981) The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 75:816–821PubMed

20.

Isebaert SF, Swinnen JV, McBride WH, Haustermans KM (2011) Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells. Int J Radiat Oncol Biol Phys 81:239–247PubMedCrossRef

21.

Kirikoshi H, Katoh M (2002) Expression of human GIPC1 in normal tissues, cancer cell lines, and primary tumors. Int J Mol Med 9:509–513PubMed

22.

Kupelian PA, Buchsbaum JC, Patel C et al (2002) Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 52:704–711PubMedCrossRef

23.

Kupelian PA, Elshaikh M, Reddy CA et al (2002) Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20:3376–3385PubMedCrossRef

24.

Lanahan AA, Chittenden TW, Mulvihill E et al (2006) Synectin-dependent gene expression in endothelial cells. Physiol Genomics 27:380–390PubMedCrossRef

25.

Lee NY, Ray B, How T, Blobe GC (2008) Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem 283:32527–32533PubMedCrossRef

26.

Ligensa T, Krauss S, Demuth D et al (2001) A PDZ domain protein interacts with the C-terminal tail of the insulin-like growth factor-1 receptor but not with the insulin receptor. J Biol Chem 276:33419–33427PubMedCrossRef

27.

Liu TF, Kandala G, Setaluri V (2001) PDZ domain protein GIPC interacts with the cytoplasmic tail of melanosomal membrane protein gp75 (tyrosinase-related protein-1). J Biol Chem 276:35768–35777PubMedCrossRef

28.

Lou X, Yano H, Lee F et al (2001) GIPC and GAIP form a complex with TrkA: a putative link between G protein and receptor tyrosine kinase pathways. Mol Biol Cell 12:615–627PubMed

29.

Mohler J, Bahnson RR, Boston B et al (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8:162–200PubMed

30.

Muders MH, Vohra PK, Dutta SK et al (2009) Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. Clin Cancer Res 15:4095–4103PubMedCrossRef

31.

Muders MH, Zhang H, Wang E et al (2009) Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Res 69:6042–6048PubMedCrossRef

32.

Muders MH, Dutta SK, Wang L et al (2006) Expression and regulatory role of GAIP-interacting protein GIPC in pancreatic adenocarcinoma. Cancer Research 66:10264–10268PubMedCrossRef

33.

Partin AW, Mangold LA, Lamm DM et al (2001) Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58:843–848PubMedCrossRef

34.

Patra CR, Rupasinghe CN, Dutta SK et al (2012) Chemically Modified Peptides Targeting the PDZ Domain of GIPC as a Therapeutic Approach for Cancer. ACS Chem Biol

35.

Pawar SC, Dougherty S, Pennington ME et al (2007) Alpha6 integrin cleavage: sensitizing human prostate cancer to ionizing radiation. Int J Radiat Biol 83:761–767PubMedCrossRef

36.

Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996PubMedCrossRef

37.

Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105PubMedCrossRef

38.

Quero L, Dubois L, Lieuwes NG et al (2011) miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiother Oncol 101:203–208PubMedCrossRef

39.

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140PubMed

40.

Roach M 3rd, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974PubMedCrossRef

41.

Roach M 3rd, Marquez C, Yuo HS et al (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33–37PubMedCrossRef

42.

Skvortsova I, Skvortsov S, Stasyk T et al (2008) Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 8:4521–4533PubMedCrossRef

43.

Strassmann G, Olbert P, Hegele A et al (2011) Advantage of robotic needle placement on a prostate model in HDR brachytherapy. Strahlenther Onkol 187:367–372PubMedCrossRef

44.

Valdembri D, Caswell PT, Anderson KI et al (2009) Neuropilin-1/GIPC1 signaling regulates alpha5beta1 integrin traffic and function in endothelial cells. PLoS Biol 7:e25PubMedCrossRef

45.

Wang L, Lau JS, Patra CR et al (2010) RGS-GAIP-interacting protein controls breast cancer progression. Mol Cancer Res 8:1591–1600PubMedCrossRef

46.

Wang L, Mukhopadhyay D, Xu X (2006) C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. FASEB J 20:1513–1515PubMedCrossRef

47.

Wang LH, Kalb RG, Strittmatter SM (1999) A PDZ protein regulates the distribution of the transmembrane semaphorin, M-SemF. J Biol Chem 274:14137–14146PubMedCrossRef

48.

Yavelsky V, Rohkin S, Shaco-Levy R et al (2008) Native human autoantibodies targeting GIPC1 identify differential expression in malignant tumors of the breast and ovary. BMC Cancer 8:247PubMedCrossRef

49.

Yoshioka Y, Suzuki O, Kobayashi K et al (2009) External-beam radiotherapy for clinically localized prostate cancer in Osaka, Japan, 1995–2006: time trends, outcome, and risk stratification. Strahlenther Onkol 185:446–452PubMedCrossRef

50.

Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95–09. J Clin Oncol 28:1106–1111PubMedCrossRef

51.

Zucca S, Carau B, Solla I et al (2011) Prostate image-guided radiotherapy by megavolt cone-beam CT. Strahlenther Onkol 187:473–478PubMedCrossRef

Titel: Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer
verfasst von: A. Singer
Y. Deuse
U. Koch
T. Hölscher
D. Pfitzmann
C. Jakob
S. Hehlgans
G.B. Baretton
A. Rentsch
M. Baumann
M.H. Muders
M. Krause
Publikationsdatum: 01.12.2012
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 12/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0228-7

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer

Abstract

Purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2012

Expander/implant breast reconstruction before radiotherapy

Clinical evaluation of a commercial surface-imaging system for patient positioning in radiotherapy

Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer

HDR brachytherapy: an option for preventing nonmalignant obstruction in patients after lung transplantation

Radiotherapy after radical prostatectomy: immediate or early delayed?

Datenbankbasierte digitale retrospektive Auswertung von Patientenkollektiven in der Radioonkologie

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie